US 9,850,489 B2 · Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity

Abstract

The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.

Claims6

Dependent claims

A method of decreasing IFN-λ1 gene activity in an airway epithelial cell, comprising the steps of:

i) providing an airway epithelial cell in need of decreasing IFN-λ1 gene activity, said airway epithelial cell is viral-stimulated;
and
ii) exposing said airway epithelial cell to a siRNA oligonucleotide targeted against GATA1 transcriptional factor, thereby decreasing IFN-λ1 gene activity in said airway epithelial cell, as indicated by a decrease in IFN-λ1 protein expression,
wherein said GATA1 mRNA has a nucleotide sequence set for in Accession No:
NM_002049.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/277,713Filed 27 Sep 2016 · division

Priority

5 May 2009

Published

US 2017/0260532 A114 Sep 2017

Granted

26 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C12N 15/1136
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against…
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides
C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…
G01N 33/5044
For testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics: involving specific cell types

Family

Application61/215,428Us provisional application · filed 5 May 2009

Application12/799,925Parent of this division · filed 5 May 2010

Application13/693,383Parent of this continuation-in-part · filed 4 Dec 2012

US 8,349,808 B2Parent of this division · filed 8 Jan 2013

Application13/771,855Parent of this continuation · filed 20 Feb 2013

US 8,802,648 B2Parent of this continuation-in-part · filed 12 Aug 2014

Application14/557,623Parent of this division · filed 2 Dec 2014

US 8,933,049 B2Parent of this continuation · filed 13 Jan 2015

US 2017/0260532 A1Pre-grant publication · published 14 Sep 2017

US 9,506,066 B2Parent of this division

Application14/557,623Parent of this continuation

Application13/771,855Parent of this continuation-in-part

Application13/693,383Parent of this division

US 2011/0237643 A1Published application

US 2013/0338211 A1Published application

US 2014/0057960 A1Published application

US 2015/0167001 A1Published application

US 9,850,489 B2This patent

From the US filing history. Foreign family members aren’t listed.

Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity

Life of this patent

Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity

Life of this patent

Abstract

Claims6